Cargando…
Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
AIM: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). METHOD: This was a double‐blind, repeat‐cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048784/ https://www.ncbi.nlm.nih.gov/pubmed/33206382 http://dx.doi.org/10.1111/dmcn.14733 |
_version_ | 1783679294328799232 |
---|---|
author | Delgado, Mauricio R Tilton, Ann Carranza‐Del Río, Jorge Dursun, Nigar Bonikowski, Marcin Aydin, Resa Maciag‐Tymecka, Iwona Oleszek, Joyce Dabrowski, Edward Grandoulier, Anne‐Sophie Picaut, Philippe |
author_facet | Delgado, Mauricio R Tilton, Ann Carranza‐Del Río, Jorge Dursun, Nigar Bonikowski, Marcin Aydin, Resa Maciag‐Tymecka, Iwona Oleszek, Joyce Dabrowski, Edward Grandoulier, Anne‐Sophie Picaut, Philippe |
author_sort | Delgado, Mauricio R |
collection | PubMed |
description | AIM: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). METHOD: This was a double‐blind, repeat‐cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home‐exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4. RESULTS: During cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2–17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of –0.4 [p=0.012] and –0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment‐related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively). INTERPRETATION: Treatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. WHAT THIS PAPER ADDS: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy. Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment. Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises. AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year. |
format | Online Article Text |
id | pubmed-8048784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80487842021-04-20 Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study Delgado, Mauricio R Tilton, Ann Carranza‐Del Río, Jorge Dursun, Nigar Bonikowski, Marcin Aydin, Resa Maciag‐Tymecka, Iwona Oleszek, Joyce Dabrowski, Edward Grandoulier, Anne‐Sophie Picaut, Philippe Dev Med Child Neurol Original Articles AIM: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). METHOD: This was a double‐blind, repeat‐cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home‐exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4. RESULTS: During cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2–17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of –0.4 [p=0.012] and –0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment‐related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively). INTERPRETATION: Treatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. WHAT THIS PAPER ADDS: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy. Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment. Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises. AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year. John Wiley and Sons Inc. 2020-11-18 2021-05 /pmc/articles/PMC8048784/ /pubmed/33206382 http://dx.doi.org/10.1111/dmcn.14733 Text en © 2020 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Delgado, Mauricio R Tilton, Ann Carranza‐Del Río, Jorge Dursun, Nigar Bonikowski, Marcin Aydin, Resa Maciag‐Tymecka, Iwona Oleszek, Joyce Dabrowski, Edward Grandoulier, Anne‐Sophie Picaut, Philippe Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study |
title | Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study |
title_full | Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study |
title_fullStr | Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study |
title_full_unstemmed | Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study |
title_short | Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study |
title_sort | efficacy and safety of abobotulinumtoxina for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048784/ https://www.ncbi.nlm.nih.gov/pubmed/33206382 http://dx.doi.org/10.1111/dmcn.14733 |
work_keys_str_mv | AT delgadomauricior efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT tiltonann efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT carranzadelriojorge efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT dursunnigar efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT bonikowskimarcin efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT aydinresa efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT maciagtymeckaiwona efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT oleszekjoyce efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT dabrowskiedward efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT grandoulierannesophie efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT picautphilippe efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy AT efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy |